As of writing, fasoracetam is being tested in Phase II/III clinical trials for attention deficit hyperactivity disorder (ADHD) [1].…
Et schreiwt de Fasoracetam Puder an de klineschen Versuchsstudien tëschent Phase II / III op Hyperaktivitéitsthema (ADHD) [1].